|本期目录/Table of Contents|

[1]汪涛,朱浩雨,卜青松,等.非小细胞肺癌EGFR突变状态与CT特征的相关性[J].中华肺部疾病杂志,2023,(01):51-54.[doi:10.3877/cma.j.issn.1674-6902.2023.01.011 ]
点击复制

非小细胞肺癌EGFR突变状态与CT特征的相关性(PDF)

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2023年01期
页码:
51-54
栏目:
临床研究
出版日期:
2023-02-20

文章信息/Info

Title:
-
作者:
汪涛; 朱浩雨; 卜青松; 胡磊; 王文娟; 方阮; 刘啸峰
247000 池州,池州市人民医院医学影像科
Author(s):
-
关键词:
非小细胞肺癌;  表皮生长因素受体;  突变状态;  计算机断层扫描
Keywords:
-
分类号:
R734.2
DOI:
10.3877/cma.j.issn.1674-6902.2023.01.011
摘要:
目的 分析计算机断层扫描(CT)纹理特征与非小细胞肺癌(non-small cell lung cancer, NSCLC)表皮生长因素受体(EGFR)突变状态的相关性。方法 选择2018年1月至2022年1月我院收治的73例NSCLC患者为对象,根据EGFR突变状态分为突变组40例和未突变组33例。筛选NSCLC EGFR突变状态非0系数的CT纹理特征,构建Lasso-Logistics回归模型,绘制受试者工作特征曲线(ROC)分析诊断效能。结果 共筛选出能量、熵、均匀度、对比度4个非0系数的CT纹理特征及气管空气征、胸膜凹陷征2个CT形态特征。ROC曲线分析显示Lasso-Logistics回归模型诊断NSCLCEGFR突变状态的AUC为0.879(95%CI 0.872～0.926),敏感度90.00%,特异度82.50%。结论 CT纹理特征气管空气征、胸膜凹陷征、能量、熵、均匀度、对比度是NSCLC患者EGFR突变状态的诊断因素,建立的诊断模型能为临床识别NSCLC EGFR突变的高危患者提供参考。
Abstract:
-

参考文献/References:

1 王洪武, 金发光. 晚期非小细胞肺癌多域整合治疗策略[J/CD]. 中华肺部疾病杂志(电子版), 2022, 15(4): 457-461.
2 王庭丰, 陈爱民, 陈 欣, 等. CTC水平与非小细胞肺癌临床及病理特征的关系[J/CD]. 中华肺部疾病杂志(电子版), 2022, 15(5): 676-678.
3 Akhurst T. Staging of non-small-cell Lung Cancer[J]. PET Clin, 2018, 13(1): 1-10.
4 Chassagnon G, Bennani S, Revel MP. Nouvelle classification TNM des cancers du poumon nonà petites cellules [New TNM classification of non-small cell lung cancer][J]. Rev Pneumol Clin, 2017, 73(1): 34-39.
5 Mei D, Luo Y, Wang Y, et al. CT texture analysis of lung adenocarcinoma: can radiomic features be surrogate biomarkers for EGFR mutation statuses[J]. Cancer Imag, 2018, 18(1): 52.
6 Digumarthy SR, Padole AM, Gullo RL, et al. Can CT radiomic analysis in NSCLC predict histology and EGFR mutation status[J]? Medicine(Baltimore), 2019, 98(1): 13963.
7 Ye SB, Li R, Shi SS. Epidermal growth factor receptor(EGFR)mutation status before and after acquired resistance to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma[J]. Zhonghua Bing Li Xue Za Zhi, 2017, 46(2): 98-101.
8 Cheung AH, Tong JH, Chung LY, et al. EGFR mutation exists in squamous cell lung carcinoma[J]. Pathology, 2020, 52(3): 323-328.
9 Tirier SM, Park J, Preußer F, et al. Pheno-seq-linking visual features and gene expression in 3D cell culture systems[J]. Sci Rep, 2019, 9(1): 12367.
10 Dietel M, Bubendorf L, Dingemans AM, et al. Diagnostic procedures for non-small-cell lung cancer(NSCLC): recommendations of the European Expert Group[J]. Thorax, 2016, 71(2): 177-184.
11 Taylor J, Manos D, Schmidt H, et al. Canadian association of radiologists:Guide on computed tomography screening for lung cancer[J]. Can Assoc Radiol J, 2017, 68(3): 334-341.
12 Suh CH, Park HS, Kim KW, et al. Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC[J]. Lung Cancer, 2018, 123(1): 60-69.
13 Yoneda K, Imanishi N, Ichiki Y, et al. Treatment of non-small cell lung cancer with EGFR-mutations[J]. J UOEH, 2019, 41(2): 153-163.
14 Zhang P, Wu X, Tang M, et al. Detection of EGFR gene mutation status from pleural effusions and other body fluid specimens in patients with lung adenocarcinoma[J]. Thorac Cancer, 2019, 10(12): 2218-2224.
15 Jiang M, Zhang Y, Xu J, et al. Assessing EGFR gene mutation status in non-small cell lung cancer with imaging features from PET/CT[J]. Nucl Med Commun, 2019, 40(8): 842-849.
16 Shen TX, Liu L, Li WH, et al. CT imaging-based histogram features for prediction of EGFR mutation status of bone metastases in patients with primary lung adenocarcinoma[J]. Cancer Imaging, 2019, 19(1): 34.
17 Tu W, Sun G, Fan L, et al. Radiomics signature: A potential and incremental predictor for EGFR mutation status in NSCLC patients, comparison with CT morphology[J]. Lung Cancer, 2019, 132(1): 28-35.
18 Liu X, Wang P, Zhang C, et al. Epidermal growth factor receptor(EGFR): A rising star in the era of precision medicine of lung cancer[J]. Oncotarget, 2017, 8(30): 50209-50220.
19 Rajaram P, Chandra P, Ticku S, et al. Epidermal growth factor receptor: Role in human cancer[J]. Indian J Dent Res, 2017, 28(6): 687-694.
20 Tsai CJ, Nussinov R. Emerging allosteric mechanism of EGFR activation in physiological and pathological contexts[J]. Biophys J, 2019, 117(1): 5-13.
21 Li X, Yin G, Zhang Y, et al. Predictive power of a radiomic signature based on 18F-FDG PET/CT images for EGFR mutational status in NSCLC[J]. Front Oncol, 2019, 9(1): 1062.
22 Shroff GS, Marom EM, Godoy MCB, et al. CT Signs in the lungs[J]. Semin Ultrasound CT MR, 2019, 40(3): 265-274.
23 Filograna L, Thali MJ. Post-mortem CT imaging of the lungs: pathological versus non-pathological findings[J]. Radiol Med, 2017, 122(12): 902-908.
24 Kramer T, Annema JT. Advanced bronchoscopic techniques for the diagnosis and treatment of peripheral lung cancer[J]. Lung Cancer, 2021, 161(1): 152-162.
25 Samhouri BF, Koo CW, Yi ES, et al. Is the combination of bilateral pulmonary nodules and mosaic attenuation on chest CT specific for DIPNECH? [J]. Orphanet J Rare Dis, 2021, 16(1): 490.
26 Ojha V, Verma M, Kumar S, et al. Imaging of the spectrum of abnormal systemic arterial supply to the lungs using dual-source CT[J]. Clin Radiol, 2021, 76(3): 2351-2354.
27 Qiao M, Jiang T, Liu X, et al. Immune checkpoint inhibitors in EGFR-mutated NSCLC: Dusk or Dawn? [J]. J Thorac Oncol, 2021, 16(8): 1267-1288.
28 Talukdar S, Emdad L, Das SK, et al. EGFR: An essential receptor tyrosine kinase-regulator of cancer stem cells[J]. Adv Cancer Res, 2020, 47(1): 161-188.
29 Park S, Ha S, Lee SH, et al. Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor[J]. PLoS One, 2018, 13(1): 0189766.
30 Sacconi B, Anzidei M, Leonardi A, et al. Analysis of CT features and quantitative texture analysis in patients with lung adenocarcinoma: a correlation with EGFR mutations and survival rates[J]. Clin Radiol, 2017, 72(6): 443-450.

备注/Memo

备注/Memo:
通信作者: 刘啸峰, Email: lxf6364@sina.com
更新日期/Last Update: 2023-02-20